» Sign in / Register

Straightforward molecular analysis for the detection of MSI associated tumors

visit product page

Microsatellite instability (MSI) is a phenotype originated from an impaired DNA mismatch repair (MMR) system and is closely related to a broad range of tumors, including gastric, endometrial and colorectal cancers. The analysis of MSI status is of growing relevance as tumors positive for MSI are more sensitive to immunotherapy[1].

The Human Target-Microsatellite Instability Plus (HT-MSI+) Kit uses fluorescent multiplex PCR to evaluate the MSI status from DNA samples of any source. HT-MSI+ analyses an expanded panel of 6 quasimonomorphic mononucleotide markers, including the five standard NR-27, NR-21, NR-24, BAT-25, BAT-26 mononucleotide repeats[2] plus the HSP110 microsatellite T17 (mononucleotide repeat retained in intron 8), whose mutation has been highly associated with MSI positive colorectal carcinomas[3,4].

HT-MSI+ analysis can be carried out on tumor cells without the need of a reference DNA sample, which facilitates a simpler experimental setup and allows for an increased number of target samples on the plate.

Figure 1: Workflow HT-MSI+ assay based on a multiplex PCR followed by Fragment Analysis

Figure 1: Workflow HT-MSI+ assay based on a multiplex PCR followed by Fragment Analysis

Questions or inquiries?

Please contact Dr. Larissa Consani Textor with all questions or inquiries you may have!

References:

[1] Chang et al. (2018) Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem. Mol. Morphol. 26 (2):e15-e21.
[2] Goel et al. (2010) An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5 (2): e9393.
[3] Dorard et al. (2011) Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat. Med. 17:1283.
[4] Berardinelli et al. (2018) Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. Oncotarget 9 (47):28691.